Clinical Trials Logo

Gastric Adenocarcinoma clinical trials

View clinical trials related to Gastric Adenocarcinoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05687617 Terminated - Gastric Cancer Clinical Trials

Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.

Start date: December 15, 2022
Phase: Phase 2
Study type: Interventional

Peritoneal disease at initial presentation for patients with gastric adenocarcinoma (GA) is frequent, with 15-31% of patients presenting with peritoneal metastases (PM) at surgical exploration. The prognosis of patients with PM is poor, overall survival (OS) ranging from 8 to 13 months, reinforcing the importance of optimal patient selection before surgical management of GA. Indocyanine Green (ICG) fluorescence imaging for intraoperative detection of PM has been described in recent literature as a useful tool in patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies to increase the detection of PM during surgery. However, the role of ICG for patients with GA, and its role during diagnosic laparoscopy (DL), remain unknown.

NCT ID: NCT04682431 Terminated - Breast Cancer Clinical Trials

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Start date: November 10, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

NCT ID: NCT04675983 Terminated - Clinical trials for Gastric Adenocarcinoma

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Start date: March 10, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of sintilimab plus ramucirumab compared to stand of care first-line chemotherapy in participants with advanced gastric or esophagogastric adenocarcinoma.

NCT ID: NCT04604132 Terminated - Clinical trials for Gastric Adenocarcinoma

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

FIDES-03
Start date: October 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy of derazantinib monotherapy or derazantinib in combination with paclitaxel and ramucirumab in patients with gastric adenocarcinoma (GAC) i.e. with human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastro-esophageal junction harboring fibroblast growth factor receptor 2 (FGFR2) genetic aberrations (GA).

NCT ID: NCT04099277 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study of LY3435151 in Participants With Solid Tumors

Start date: October 28, 2019
Phase: Phase 1
Study type: Interventional

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

NCT ID: NCT04089904 Terminated - Clinical trials for Gastric Adenocarcinoma

Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

Start date: October 11, 2019
Phase: Phase 2
Study type: Interventional

To determine the pathologic complete response (pCR) rate in patients with cT1b-T2N0 GEA treated with neoadjuvant pembrolizumab followed by surgical resection.

NCT ID: NCT04060342 Terminated - Clinical trials for Non-small Cell Lung Cancer

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Start date: August 13, 2019
Phase: Phase 1
Study type: Interventional

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

NCT ID: NCT04032704 Terminated - Prostate Cancer Clinical Trials

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Start date: October 9, 2019
Phase: Phase 2
Study type: Interventional

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

NCT ID: NCT03735290 Terminated - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

ILIAD
Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab. The Phase 1b study will determine the optimal dose and schedule of ilixadencel. Patients in the Phase 2 part of the study will be randomly assigned to receive either ilixadencel (at the dose determined in Phase 1b) combined with the CPI, or only the CPI. Note: Recruitment to Phase 1b of the study has been completed.

NCT ID: NCT03122548 Terminated - Clinical trials for Gastric Adenocarcinoma

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Start date: August 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether CRS-207 in combination with pembrolizumab is safe and effective in adults with recurrent or metastatic gastric, gastroesophageal junction, or esophageal cancer who have received one or two prior chemotherapy regimens for advanced disease.